Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support - Summary - MDSpire

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

  • By

  • Dan Qiao

  • Lei Nie

  • Shuang Liu

  • Hai-bin Ding

  • June 17, 2026

  • 0 min

Share

Objective:

To report a case of sustained grade 4 thrombocytopenia following adjuvant T-DM1 therapy and to evaluate the clinical management of this condition.

Key Findings:
  • 01
Interpretation:

Remove this section as it contains unsupported claims.

Limitations:
  • The case study is based on a single patient, limiting generalizability.
  • Long-term outcomes and efficacy of romiplostim in this context require further investigation.
Conclusion:

Revise to focus solely on the findings without implications or recommendations.

Original Source(s)

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

  • by Dan Qiao, Lei Nie, Shuang Liu, Hai-bin Ding

  • June 17, 2026

Related Content

Clinical significance of lesion conspicuity on contrast-enhanced mammography

Editorial: Immune-related biomarkers in skin and breast cancer: innovations in immunological diagnostics and therapies

Homologous recombination pathway alterations in basal-like breast cancer